Briacell Therapeutics Stock Price, News & Analysis
Company Description
Briacell Therapeutics (NASDAQ: BCTXL) is a publicly traded company in the Pharmaceutical Preparations sector.
BCTXL stock has gained 12.8% over the past year. Shares last traded at $1.05.
On a trailing twelve-month basis, Briacell Therapeutics reported net income of -$26.3M and diluted earnings per share of $-62.19.
This page provides a comprehensive overview of BCTXL stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Briacell Therapeutics (BCTXL) stock last traded at $1.05. Over the past 12 months, the stock has gained 12.8%.
Latest News
SEC Filings
Briacell Therapeutics has filed 3 recent SEC filings, including 1 Form 8-K, 1 Form 25-NSE, 1 Form DEF 14A. The most recent filing was submitted on March 31, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all BCTXL SEC filings →
Financial Highlights
operating income reached -$27.2M, and net income was -$26.3M. Diluted earnings per share stood at $-62.19. The company generated -$28.2M in operating cash flow. With a current ratio of 3.42, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Briacell Therapeutics (BCTXL) currently stands at 3.6 thousand shares, up 30316.7% from the previous reporting period, representing 0.1% of the float. Over the past 12 months, short interest has decreased by 52.1%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Briacell Therapeutics (BCTXL) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
BCTXL Company Profile & Sector Positioning
Briacell Therapeutics (BCTXL) operates in the Pharmaceutical Preparations sector and is listed on the NASDAQ.